[go: up one dir, main page]

WO2004063394A3 - Utilisation de substances se fixant a fabp4 pour le diagnostic et le traitement du carcenome de la vessie - Google Patents

Utilisation de substances se fixant a fabp4 pour le diagnostic et le traitement du carcenome de la vessie Download PDF

Info

Publication number
WO2004063394A3
WO2004063394A3 PCT/DE2004/000029 DE2004000029W WO2004063394A3 WO 2004063394 A3 WO2004063394 A3 WO 2004063394A3 DE 2004000029 W DE2004000029 W DE 2004000029W WO 2004063394 A3 WO2004063394 A3 WO 2004063394A3
Authority
WO
WIPO (PCT)
Prior art keywords
fabp4
diagnosing
bladder carcinoma
treating bladder
substances binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2004/000029
Other languages
German (de)
English (en)
Other versions
WO2004063394A2 (fr
Inventor
Bernd Hinzmann
Edgar Dahl
Thomas Specht
Christian Pilarsky
Alexander Herr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2004063394A2 publication Critical patent/WO2004063394A2/fr
Publication of WO2004063394A3 publication Critical patent/WO2004063394A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/57557—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne l'utilisation de FABP4 pour le diagnostic et le traitement de tumeurs urogénitales, en particulier du carcinome de la vessie, ainsi que pour le criblage de substances devant être utilisées à ces fins.
PCT/DE2004/000029 2003-01-10 2004-01-08 Utilisation de substances se fixant a fabp4 pour le diagnostic et le traitement du carcenome de la vessie Ceased WO2004063394A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10300861.6 2003-01-10
DE10300861A DE10300861A1 (de) 2003-01-10 2003-01-10 Verwendung von an FABP4 bindenden Substanzen zur Diagnose und Behandlung des Harnblasenkarzinoms

Publications (2)

Publication Number Publication Date
WO2004063394A2 WO2004063394A2 (fr) 2004-07-29
WO2004063394A3 true WO2004063394A3 (fr) 2004-10-14

Family

ID=32519867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2004/000029 Ceased WO2004063394A2 (fr) 2003-01-10 2004-01-08 Utilisation de substances se fixant a fabp4 pour le diagnostic et le traitement du carcenome de la vessie

Country Status (2)

Country Link
DE (1) DE10300861A1 (fr)
WO (1) WO2004063394A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499864B2 (en) 2003-11-03 2016-11-22 Aab Patent Holding Aps Expression of FABP4 and other genes associated with bladder cancer progression
AU2008292091A1 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S RNA antagonist compounds for the modulation of FABP4/aP2
CN110438127A (zh) * 2019-08-09 2019-11-12 中国药科大学 抑制FABP4靶基因表达的siRNA及其应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BENNETT J H ET AL.: "Immunohistochemical identification of tumours of adipocytic differentiation using an antibody to aP2 protein", JOURNAL OF CLINICAL PATHOLOGY, vol. 48, 1995, pages 950 - 954, XP008031677 *
CELIS A ET AL.: "Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities", ELECTROPHORESIS, vol. 20, no. 2, 1999, pages 355 - 361, XP002287087 *
CELIS J E ET AL.: "Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas", CANCER RESEARCH, vol. 56, no. 20, 1999, pages 4782 - 4790, XP001189628 *
GROMOVA I ET AL.: "Protein abundancy and mRNA levels of the adipocyte-type fatty acid binding protein correlate in non-invasive and invasive bladder transitional cell carcinomas", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 13, 1998, pages 379 - 383, XP008031678 *
VAN DONGEN M J P ET AL.: "Structure-based screening as apllied to human FABP4: A highly efficient alternative to HTS for hit generation", THE JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, 9 October 2002 (2002-10-09), pages 11874 - 11880, XP002287088 *
YANG T T ET AL.: "aP2 protein expression as a diagnostic marker in soft tissue tumours", SARCOMA, no. 5, 2001, pages 139 - 142, XP008031680 *

Also Published As

Publication number Publication date
WO2004063394A2 (fr) 2004-07-29
DE10300861A1 (de) 2004-07-22

Similar Documents

Publication Publication Date Title
WO2005047314A3 (fr) Peptides supportes et peptides fixant a fgf-5
WO2004050707A3 (fr) Molecules de reconnaissance specifiques de tumeurs
WO2004058171A3 (fr) Anticorps anti-gpr64 et utilisations
WO2007061874A3 (fr) Procedes et compositions utilises dans le traitement du cancer
WO2005030144A3 (fr) Composes de pyrrolopyridazine, et procedes pour les utiliser pour traiter des troubles de proliferation
WO2007133290A8 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2000028090A3 (fr) Essais diagnostiques du cancer
WO2003048301A3 (fr) Anticorps anti-hla-dr et leurs methodes d'utilisation
WO2004034990A3 (fr) Methodes et compositions a utiliser dans le traitement du cancer
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
WO2005097832A3 (fr) Anticorps anti-tgf-$g(b) humanises
EP2230254A3 (fr) Combinaisons thérapeutiques d'anticorps anti-igfr1
WO2006058237A3 (fr) Substrats revetus de polymere destines a fixer des biomolecules et procedes de fabrication et d'utilisation correspondants
WO2003082208A8 (fr) Composes de pyrrolopyridazine et methodes d'utilisation de ces composes pour le traitement de maladies proliferatives
WO2009036427A3 (fr) Biomarqueurs du cancer de la prostate
WO2008151819A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
WO2005118878A3 (fr) Methodes de criblage de proliferation cellulaire ou de troubles neoplasiques
WO2004074324A3 (fr) Modulation de la fonction du recepteur du poliovirus
WO2007051164A3 (fr) Modulateurs du recepteur de type toll 3, et leurs procedes et utilisations
MXPA03002323A (es) Metodos de diagnostico de cancer colorectal, composiciones y metodos para seleccionar moduladores de cancer colorectal.
WO2005087793A3 (fr) Compositions immunostimulatrices et leurs utilisations
EP2261256A3 (fr) Procedes d'inhibition de metastases
WO2003093794A3 (fr) Procedes relatifs a la decouverte de biomarqueurs et au diagnostic de tumeurs
WO2005053604A3 (fr) Anticorps specifiques de l'antigene sm5-1 associe au cancer et utilisations associees
WO2005085861A3 (fr) Acides nucleiques et polypeptides codes destines a etre utilises dans des troubles hepatiques et du cancer epithelial

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established
122 Ep: pct application non-entry in european phase